A systems model of altered consciousness: Integrating natural and drug-induced psychoses

Brain Research Bulletin

Volumn 56, Issue 5, 2001, Pages 495-507

  Vollenweider, Franz X ^a   Geyer, Mark A ^b  

^a UNIVERSITY HOSPITAL OF PSYCHIATRY   (Switzerland)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Model psychosis; NMDA antagonist (ketamine); Positron Emission Tomography (PET); Prepulse inhibition of the acoustic startle (PPI); Schizophrenia; Serotonin 2A agonist (psilocybin)

Indexed keywords

KETAMINE; N METHYL DEXTRO ASPARTIC ACID; PSILOCYBINE;

BRAIN CORTEX; CONFERENCE PAPER; DRUG INDUCED DISEASE; HALLUCINATION; HUMAN; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PSYCHOSIS; SCHIZOPHRENIA; STARTLE REFLEX; STRIATE CORTEX; SYMPTOMATOLOGY; THALAMUS;

ANIMALS; BRAIN; CONSCIOUSNESS DISORDERS; HALLUCINOGENS; HUMANS; MODELS, NEUROLOGICAL; NEURAL PATHWAYS; PSYCHOSES, SUBSTANCE-INDUCED; RECEPTORS, N-METHYL-D-ASPARTATE; SCHIZOPHRENIA;

EID: 0035891880     PISSN: 03619230     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0361-9230(01)00646-3     Document Type: Conference Paper

References (158)

1. LSD and phenethylamine hallucinogens: Common sites of neuronal action
2. Serotonin and hallucinogens
3. Parallel organization of functionally segregated circuits linking basal ganglia and cortex
4. The role of the thalamus in schizophrenia
5. "Cognitive dysmetria" as an integrative theory of schizophrenia: A dysfunction in cortical-subcortical-cerebellar circuitry?
6. The dissociative anesthetics, ketamine and phencyclidine selective reduce excitation of central mammalian neurons by N-methyl-D-aspartate
7. Metabotropic glutamate receptors: Electrophysiological properties and role in plasticity
8. Serotonin 2 (5-HT2) receptor binding in the frontal cortex of schizophrenic patients
9. Noradrenergic innervation of the thalamic reticular nucleus: A light and electron microscopic immunohistochemical study in rats
10. Light and electron microscopic evidence for a GABAergic projection from the caudal basal forebrain to the thalamic reticular nucleus in rats
11. Antagonism of phencyclidine-induced deficits in prepulse inhibition by the putative atypical antipsychotic olanzapine
12. Multiple limbic regions mediate the disruption of prepulse inhibition produced in rats by the noncompetitive NMDA antagonist dizocilpine
13. Pathogenesis of acute schizophrenic psychosis
14. "Psychedelic" experiences in acute psychoses
15. Sensorimotor gating and schizophrenia: Human and animal model studies
16. Prestimulus effects on human startle reflex in normals and schizophrenics
17. Gating and habituation deficits in the schizophrenia disorders
18. Association of ketamine-induced psychosis with focal activation of the prefrontal cortex in healthy volunteers
19. Patterns of metabolic activity in the treatment of schizophrenia
20. Striatal metabolic rate and clinical response to neuroleptics in schizophrenia
21. PET and MRI of the thalamus in never-medicated patients with schizophrenia
22. Schizophrenia: A subcortical neurotransmitter imbalance syndrome?
23. Prefrontal and temporal blood flow in schizophrenia: Resting and activation technetium-99m-hmpao spect patterns in young neuroleptic-naive patients with acute disease
24. The early symptoms of schizophrenia
25. Increased frontal and reduced parietal glucose metabolism in acute untreated schizophrenia
26. Determination of the transfer ratio of cat's geniculate neurons through quasi-intracellular recordings and the relation with the level of alertness
27. Neuronal phenomena associated with vigilance and consciousness: From cellular mechanisms to electroencephalographic patterns
28. Ketamine and the conscious mind
29. Function of the thalamic reticular complex: The searchlight hypothesis
30. Frontal cortical and left temporal glutamatergic dysfunction in schizophrenia
31. Decreased hippocampal (CA3) NMDA receptors in schizophrenia
32. Increased temporal lobe glucose use in chronic schizophrenic patients
33. Psychological aspects of altered states of consciousness of the LSD type: Measurements of their basic dimensions and prediction of individual differences
34. The standardized psychometric assessment of altered states of consciousness (ASCs) in humans
35. International study on altered states of consciousness (ISASC). Summary of the results
36. Hyperactivity of the left striato-pallidal projection. Part I: Lower level theory
37. Left globus pallidus abnormality in never-medicated patients with schizophrenia
38. Hypofrontality revisited: A high resolution single photon emission computed tomography study in schizophrenia
39. Personality trait dependent performance under psilocybin
40. Dreams, hallucinogenic drug states, and schizophrenia: A psychological and biological comparison
41. Early subjective experiences in schizophrenic episodes
42. Drugs which antagonize 5-hydroxytryptamine
43. Behavioral studies of hallucinogenic drugs in animals: Implications for schizophrenia research
44. Startle habituation and sensorimotor gating in schizophrenia and related animal models
45. The effects of M100907 in pharmacological and developmental animal models of prepulse inhibition deficits in schizophrenia
46. Increased startle responding in rats treated with phencyclidine
47. Multiple transmitters modulate prepulse inhibition of startle: Relevance to schizophrenia
48. Startle response models of sensorimotor gating and habituation deficits in schizophrenia
49. Habituation of tactile startle is altered by drugs acting on serotonin-2 receptors
50. Toward an integrated neurobiology of panic disorder
51. Psychedelische Erlebnisse zu Beginn produktiver Episoden endogener Psychosen
52. Hallucinogenic drug induced states resemble acute endogenous psychoses: Results of an empirical study
53. Neurometabolic effects of psilocybin, 3,4-methylenedioxyethylamphetamine (MDE) and d-methamphetamine in healthy volunteers
54. Modulation of semantic priming effects by psilocybin, MDE (ecstasy), and d-methamphetamine
55. NR2B-containing NMDA receptors are up-regulated in temporal cortex in schizophrenia
56. Alterations in the cortical serotonergic system in schizophrenia: A postmortem study
57. Cholinergic innervation of the human thalamus: Dual origin and differential nuclear distribution
58. Models of experience and behavior in psychotic disorders
59. Mescaline-induced psychopathological, neuropsychological, and neurometabolic effects in normal subjects: Experimental psychosis as a tool for psychiatric research
60. Blood flow and cerebral laterality in the mescaline model of pychosis
61. Zur bedeutung der modellpsychosen
62. Beziehungen der modell- bzw. Drogenpsychosen zu schizophrenen erkrankungen
63. Increases in strychnine-insensitive glycine binding sites in cerebral cortex of chronic schizophrenics: Evidence for glutamate hypothesis
64. Phencyclidine increases forebrain monoamine metabolism in rats and monkeys: Modulation by the isomers of HA966
65. Serotonin uptake sites and serotonin receptors are altered in the limbic system of schizophrenics
66. Preliminary evidence of an association between sensorimotor gating and distractibility in psychosis
67. The effect of ketamine on pre-pulse inhibition and attention
68. Similarity of schizophrenia and the psilocybin syndrome as determined by objective methods
69. Failure of haloperidol to block the effects of phencyclidine and dizocilpine on prepulse inhibition of startle
70. Low cerebrospinal fluid glutamate in schizophrenic patients and a new hypothesis on schizophrenia
71. [3H]MK-801 binding sites in postmortem brain regions of schizophrenic patients
72. Modulation of phencyclidine-induced changes in locomotor activity and patterns in rats by serotonin
73. Dissociation of ketamine effects on rule acquisition and rule implementation: Possible relevance to NMDA receptor contributions to executive cognitive functions
74. Interactive effects of subanesthetic ketamine and subhypnotic lorazepam in humans: Psychotomimetic, perceptual, cognitive and neuroendocrine responses
75. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans
76. Ketamine activates psychosis and alters limbic blood flow in schizophrenia
77. Selective abnormalities of prefrontal serotonergic receptors in schizophrenia
78. Patterns of cerebral blood flow in schizophrenia
79. A decade of serotonin research: Role of serotonin in treatment of psychosis. Serotonergic basis of antipsychotic drug effects in schizophrenia
80. Synaptic distribution of afferents from reticular nucleus in ventroposteriornucleus of cat thalamus
81. Clozapine blunts N-methyl-D-aspartate antgonist-induced psychosis: A study with ketamine
82. Ketamine-induced exacerbation of psychotic symptoms and cognitive impairment in neuroleptic-free schizophrenics
83. NMDA receptor function and human cognition: The effects of ketamine in healthy volunteers
84. Dopaminergic stimulation disrupts sensorimotor gating in the rat
85. Indoleamine and the phenethylamine hallucinogens: Mechanisms of psychotomimetic action
86. The effects of psilocybin on primary process content in language
87. Symptom differences in schizophrenia with good and poor prognosis
88. Dexfenfluramine and serotnin neurotoxicity: Further precline evidence that clinical caution is indicated
89. Disorders of attention and perception in early schizophrenia
90. The role of serotonin in schizophrenia and the place of serotonin- dopamine antagonist antipsychotics
91. Recent advances in the pharmacotherapy of schizophrenia
92. The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia
93. Visual pathways to perception and action
94. Frontal lobes and the temporal organisation of memory
95. Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats
96. The use of interspecies scaling in toxicokinetics
97. Brain stem reticular formation and activation of the EEG
98. NMDA antagonists neurotoxicity: Mechanism and prevention
99. Sensorimotor gating and thought disturbance measured in close temporal proximity in schizophrenic patients
100. The attention system of the human brain
101. Memory disturbances in "ecstasy" users are correlated with an altered brain serotonin neurotransmission
102. Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin
103. Untersuchungen mit psilocybin, einer psychotropen substanz aus psilocybe mexicana. Schweiz
104. Correlation of positive symptoms exclusively to hyperperfusion or hypoperfusion of cerebral cortex in never-treated schizophrenics
105. Ego-pychopathology: The concept and its empirical evaluation
106. Paranoid-halluzinatorische zustandsbilder bei drogeninduzierten psychosen
107. The psilocybin psychosis as a model psychosis paradigma for acute schizophrenia: A PET study with 18-FDG
108. Cerebral metabolic activity correlates of subsyndromes in chronic schizophrenia
109. 15O Positron emission tomography scanning in predominantly never-treated acute schizophrenic patients
110. Deficient NMDA-mediated glutamate release from synaptosomes of schizophrenics
111. Functional organization of thalamocortical relays
112. The control of retinogeniculate transmission in the mammalian lateral geniculate nucleus
113. Cortical-striatal-thalamic circuits and brain glucose metabolic activity in 70 unmedicated male schizophrenic patients
114. A functional neuroanatomy of hallucinations in schizophrenia
115. Control of thalamic transmission by corticofugal and ascending reticular pathways in the visual system
116. 2c receptors
117. DOI disrupts prepulse inhibition of startle in rats via 5-HT2A receptors in the ventral pallidum
118. The functional neuroanatomy of awareness: With a focus on the role of various anatomical systems in the control of intermodal attention
119. GABAergic interneurons in the somatosensory thalamus of the guinea-pig: A light and ultrastructural immunocytochemical investigation
120. Cellular thalamic mechanisms
121. Reticularis thalami neurons revisited: Activity changes during shifts of states of vigilance
122. Thalamocortical oscillations in the sleeping and aroused brain
123. Cholinergic and non-cholinergic neurons of cat basal forebrain project to reticular and mediodorsal thalamic nuclei
124. Seroquel restores sensorimotor gating in phencyclidine-treated rats
125. Seroquel, clozapine and chlorpromazine restore sensorimotor gating in ketamine-treated rats
126. Schizophrenic-like sensorimotor gating abnormalities in rats following dopamine infusion into the nucleus accumbens
127. The neural substrates of sensorimotor gating of the starle reflex: A review of the recent findings and their implications
128. Using an animal model of deficient sensorimotor gating to study the pathophysiology and new treatments of schizophrenia
129. The effects of spiperone, SCH 23390 and clozapine on apomorphine-inhibition of sensorimotor gating of the startle response in the rat
130. Dopamine, schizophrenia, mania, and depression: Toward a unified hypothesis of cortico-striato-pallido-thalamic function
131. Towards a cross-species pharmacology of sonsorimotor gating: Effects of amantadine, bromocriptine, pergolide and ropinirole on prepulse inhibition of acoustic startle in rats
132. Personality trait dependent performance under psilocybin. II
133. Radioligand binding evidence implicates the brain 5-HT2 receptor as a site of action for LSD and phenylisopropylamine hallucinogens
134. 2A receptor antagonist and putative antipsychotic, blocks dizocilpine-induced prepulse inhibition deficits in sprague-dawley and wistar rats
135. The use of psychotomimetics in schizophrenia research with special emphasis on the PCP/ketamine model psychosis [Die Anwendung von Psychotomimetika in der Schizophrenieforschung unter besonderer Berücksichtigung der Ketamin/PCP-Modell-Psychose]
136. Evidence for a cortical-subcortical dysbalance of sensory information processing during altered states of consciousness using PET and FDG
137. Advances and pathophysiological models of hallucinogen drug actions in humans: A preamble to schizophrenia research
138. Differential psychopathology and patterns of cerebral glucose utilisation produced by (S)- and (R)-ketamine in healthy volunteers measured by FDG-PET
139. Atypical antipsychotics (clozapine, sertindole) attenuate information processing deficits and metabolic hyperactivity in the NMDA-antagonist model of psychosis
140. Sertindole reduces S-ketamine induced attentional deficits in healthy volunteers
141. Wirkung von midazolam auf die ketamin-induzierte modellpsychose
142. Metabolic hyperfrontality and psychopathology in the ketamine model of psychosis using positron emission tomography (PET) and [F-18]-fluorodeoxyglocose (FDG)
143. Positron emission tomography and fluorodeoxyglucose studies of metabolic hyperfrontality and psychopathology in the psilocybin model of psychosis
144. Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action
145. 5-HT modulation of dopamine release in basal ganglia in psilocybin-induced psychosis in man: A PET study with [11C]raclopride
146. Effects of S-ketamine on striatal dopamine release: A [11C] raclopride PET study of a model psychosis in humans
147. The syndrome concept: History and statistical operationalizations
148. Effective neuroleptic medication removes prepulse inhibition deficits in schizophrenia patients
149. Persistance of cerebral metabolic abnormalities in chronic schizophrenia as determined by positron emission tomography
150. A biochemical and pharmacological suggestion about certain mental disorders